Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations

Transplant Infectious Disease

Volumn 18, Issue 5, 2016, Pages 699-705

  Cohen, S A ^a,b   Woodfield, M C ^a   Boyle, N ^a   Stednick, Z ^a   Boeckh, M ^a,b   Pergam, S A ^a,b,c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

bacteremia; fungemia; hematopoietic cell transplant; Lactobacillus; over the counter; probiotic

Indexed keywords

CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; GENTAMICIN; LEVOFLOXACIN; NON PRESCRIPTION DRUG; PENICILLIN DERIVATIVE; PROBIOTIC AGENT; VANCOMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIUM; BIFIDOBACTERIUM; BLOOD CULTURE; BLOODSTREAM INFECTION; CATHETER REMOVAL; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; FEVER; FUNGEMIA; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LACTOBACILLUS; MALE; MIDDLE AGED; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SACCHAROMYCES; SCHOOL CHILD; STATISTICAL ANALYSIS; STREPTOCOCCUS THERMOPHILUS; WASHINGTON; YOUNG ADULT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; BLOOD; COMPLICATION; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE TREATMENT; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOGENICITY; SACCHAROMYCES CEREVISIAE;

ADULT; AGED; BACTEREMIA; BIFIDOBACTERIUM; BLOOD CULTURE; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; LACTOBACILLUS; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; PROBIOTICS; RETROSPECTIVE STUDIES; SACCHAROMYCES CEREVISIAE; STREPTOCOCCUS THERMOPHILUS; TRANSPLANT RECIPIENTS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84989325833     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12587     Document Type: Article

References (28)

1. Sullivan Å, Nord CE. The place of probiotics in human intestinal infections. Int J Antimicrob Agents 2002; 20 (5): 313–319.
2. Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin Infect Dis 2008; 46 (S2): S96–S100.
3. Khailova L, Frank DN, Dominguez JA, et al. Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis. Anesthesiology 2013; 119 (1): 166–177.
4. Johnston BC, Ma SSY, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012; 157 (12): 878–888.
5. D'Souza AL, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324 (7350): 1361.
6. Shadnoush M, Hosseini RS, Khalilnezhad A, et al. Effects of probiotics on gut microbiota in patients with inflammatory bowel disease: a double-blind, placebo-controlled clinical trial. Korean J Gastroenterol 2015; 65 (4): 215–221.
7. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335 (7610): 80.
8. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis 2008; 46 (Suppl 2): S67–S72.
9. Stanton C, Gardiner G, Meehan H, et al. Market potential for probiotics. Am J Clin Nutr 2001; 73 (2): 476S–483S.
10. Meini S, Laureano R, Fani L, et al. Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature. Infection 2015; 43 (6): 777–781.
11. Haghighat L, Crum-Cianflone NF. The potential risks of probiotics among HIV-infected persons: bacteraemia due to Lactobacillus acidophilus and review of the literature. Int J STD AIDS 2015; Jun 30. pii: 0956462415590725. [Epub ahead of print].
12. Snydman DR. The safety of probiotics. Clin Infect Dis 2008; 46 (Suppl 2): S104–S111.
13. Ladas EJ, Bhatia M, Chen L, et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplant 2016; 51 (2): 262–266.
14. Miles-Jay A, Butler-Wu S, Rowhani-Rahbar A, et al. Incidence rate of fluoroquinolone-resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplantation patients during an era of levofloxacin prophylaxis. Biol Blood Marrow Transplant 2015; 21 (3): 539–545.
15. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15 (10): 1143–1238.
16. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15 (6): 825–828.
17. McFarland LV. From yaks to yogurt: the history, development, and current use of probiotics. Clin Infect Dis 2015; 60 (Suppl 2): S85–S90.
18. Rajagopal N. The North American probiotics market. Natural Products Insider.com. Available at: http://www.naturalproductsinsider.com/articles/2012/10/the-north-american-probiotics-market.aspx (Accessed November 11, 2015).
19. Saldanha LG. US Food and Drug Administration regulations governing label claims for food products, including probiotics. Clin Infect Dis 2008; 46 (s2): S119–S121.
20. Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35 (10): 1155–1160.
21. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38 (1): 62–69.
22. Lee MR, Tsai CJ, Liang SK, Lin CK, Huang YT, Hsueh PR. Clinical characteristics of bacteraemia caused by Lactobacillus spp. and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2000–2014. Int J Antimicrob Agents 2015; 46 (4): 439–445.
23. Simkins J, Kaltsas A, Currie BP. Investigation of inpatient probiotic use at an academic medical center. Int J Infect Dis 2013; 17 (5): e321–e324.
24. Wada M, Nagata S, Saito M, et al. Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer 2010; 18 (6): 751–759.
25. Riquelme AJ, Calvo MA, Guzmán AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36 (1): 41–43.
26. Muñoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40 (11): 1625–1634.
27. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115 (1): 178–181.
28. Saxelin M. Probiotic formulations and applications, the current probiotics market, and changes in the marketplace: a European perspective. Clin Infect Dis 2008; 46 (S2): S76–S79.